血液透析中透析液钾浓度、血钾、死亡率与心律失常事件:透析预后与实践模式研究(DOPPS)结果
该前瞻性队列研究纳入DOPPS 1至5期(1996-2015年)20个国家55,183例维持性血液透析患者,分析透析液钾浓度与全因死亡及心律失常复合结局的关联。中位随访16.5个月,24%患者死亡、7%发生心律失常复合结局;透析液钾3 vs 2 mEq/L的校正HR分别为0.96(95%CI 0.91-1.01)和0.98(95%CI 0.88-1.08),无 meaningful 差异。
要点
- 透析液钾3 vs 2 mEq/L与全因死亡(校正HR 0.96,95%CI 0.91-1.01)及心律失常复合结局(校正HR 0.98,95%CI 0.88-1.08)无 meaningful 差异。
- 透析液钾浓度每升高1 mEq/L,透析前血钾仅升高0.09(95%CI 0.05-0.14)mEq/L。
- 较高血钾水平与不良结局相关;作者认为减少高血钾相关风险或需关注饮食钾教育及钾结合剂等措施。
核心结论
- 总体结果提示,为降低高血钾相关风险,改变透析液钾浓度之外的方法(如饮食钾来源教育及钾结合剂处方)可能值得进一步关注。
研究设计与样本
- 前瞻性队列研究,纳入透析预后与实践模式研究(DOPPS)1至5期(1996-2015年)20个国家的55,183例患者。
- 预测指标为研究入组时透析液钾浓度;采用Cox回归校正潜在混杂因素,评估其与全因死亡及心律失常复合结局的关联。
主要发现
- 中位随访16.5个月期间,24%患者死亡,7%发生心律失常复合结局。
- 透析液钾3 vs 2 mEq/L的校正HR:全因死亡0.96(95%CI 0.91-1.01),心律失常复合结局0.98(95%CI 0.88-1.08)。
- 在透析前血钾各水平中结果相似;较高血钾水平与不良结局相关。
- 透析液钾浓度每升高1 mEq/L,透析前血钾仅升高0.09(95%CI 0.05-0.14)mEq/L。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏实际给予(而非处方)的透析液钾浓度及透析后血钾数据。
- 可能存在未测量的混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sudden death is a leading cause of death in patients on maintenance hemodialysis therapy. During hemodialysis sessions, the gradient between serum and dialysate levels results in rapid electrolyte shifts, which may contribute to arrhythmias and sudden death. Controversies exist about the optimal electrolyte concentration in the dialysate; specifically, it is unclear whether patient outcomes differ among those treated with a dialysate potassium concentration of 3 mEq/L compared to 2 mEq/L. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 55,183 patients from 20 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS) phases 1 to 5 (1996-2015). PREDICTOR: Dialysate potassium concentration at study entry. OUTCOMES: Cox regression was used to estimate the association between dialysate potassium concentration and both all-cause mortality and an arrhythmia composite outcome (arrhythmia-related hospitalization or sudden death), adjusting for potential confounders. RESULTS: During a median follow-up of 16.5 months, 24% of patients died and 7% had an arrhythmia composite outcome. No meaningful difference in clinical outcomes was observed for patients treated with a dialysate potassium concentration of 3 versus 2 mEq/L (adjusted HRs were 0.96 [95% CI, 0.91-1.01] for mortality and 0.98 [95% CI, 0.88-1.08] for arrhythmia composite). Results were similar across predialysis serum potassium levels. As in prior studies, higher serum potassium level was associated with adverse outcomes. However, dialysate potassium concentration had only minimal impact on serum potassium level measured predialysis (+0.09 [95% CI, 0.05-0.14] mEq/L serum potassium per 1 mEq/L greater dialysate potassium concentration). LIMITATIONS: Data were not available for delivered (vs prescribed) dialysate potassium concentration and postdialysis serum potassium level; possible unmeasured confounding. CONCLUSIONS: In combination, these results suggest that approaches other than altering dialysate potassium concentration (eg, education on dietary potassium sources and prescription of potassium-binding medications) may merit further attention to reduce risks associated with high serum potassium levels.
引用
- Karaboyas A, Zee J, Brunelli SM, et al. Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2016. PMID: 27866964. doi:10.1053/j.ajkd.2016.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。